Chris Miles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chris Miles has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Elijah Raphael Behr
Cardiovascular Research Institute, School of Health and Medical Sciences, City St. George’s, University of London, United Kingdom (J.P.R.W., E.R.B., C.J.C., R.W.).
8 shared publications - Sanjay Sharma
Cardiovascular and Genomics Research Institute, City St. George’s, University of London
6 shared publications - Michael Papadakis
Cardiovascular CAG and Cardiology Research Centre, City St. George’s University of London , Cranmer Terrace, London SW17 0RE
5 shared publications Hamish MacLachlan
Cardiovascular and Genomics Research Institute, City St. George's, University of London, London, United Kingdom
4 shared publications- Belinda Gray
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
3 shared publications - Chiara Scrocco
Cardiovascular and Genomics Research Institute School of Health and Medical Sciences City St George's, University of London, London, United Kingdom; Cardiovascular Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (6) , 102842
Posterior Electrical Axis Deviation Is Associated With Future Development of Left Bundle Branch Block
- 17 June 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (6) , 102842
Open AccessPosterior Electrical Axis Deviation Is Associated With Future Development of Left Bundle Branch Block
- Open Access
- 3 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (19) , 1803-1815
High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial
Background and Aims: The feasibility and impact of high intensity exercise programmes in patients with hypertrophic cardiomyopathy (HCM) are unknown. This study was conducted to determine the feasibility of a high intensity exercise programme and explore safety and efficacy outcomes in patients with HCM. Methods: Participants were randomized to a 12-week supervised exercise programme (n = 40) in addition to usual care, or usual care alone (n = 40). All participants underwent assessment at baseline and 12 weeks. The exercise group was re-evaluated 6 months post-programme. Feasibility was assessed by (i) recruitment, adherence, and retention rates; (ii) staffing ratios; (iii) logistics; and (iv) acceptability of the intervention. The primary exploratory safety outcome was a composite of arrhythmia-related events. Exploratory secondary outcomes included changes in (i) cardiorespiratory fitness; (ii) cardiovascular risk factors; and (iii) quality of life, anxiety, and depression scores. Results: Overall, 67 (84%) participants completed the study (n = 34 and n = 33 in the exercise and usual care groups, respectively). Reasons for non-adherence included travel, work, and family commitments. Resource provision complied with national cardiac rehabilitation standards. There was no difference between groups for the exploratory safety outcome (P = .99). At 12 weeks, the exercise group had a greater increase in peak oxygen consumption (VO2) [+4.1 mL/kg/min, 95% confidence interval (CI) 1.1, 7.1] and VO2 at anaerobic threshold (+2.3 mL/kg/min, 95% CI 0.4, 4.1), lower systolic blood pressure (−7.3 mmHg, 95% CI −11.7, −2.8) and body mass index (−0.8 kg/m2, 95% CI −1.1, −0.4), and greater improvement in hospital anxiety (−3, 95% CI −4.3, −1.7) and depression (−1.7, 95% CI −2.9, −0.5) scores, compared to the usual care group. Most exercise gains dissipated at 6 months. Conclusions: A high intensity exercise programme is feasible in patients with HCM, with apparent cardiovascular and psychological benefits, and no increase in arrhythmias. A large-scale study is required to substantiate findings and assess long-term safety of high intensity exercise in HCM.
- 3 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (19) , 1803-1815
Open AccessHigh intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial
Background and Aims: The feasibility and impact of high intensity exercise programmes in patients with hypertrophic cardiomyopathy (HCM) are unknown. This study was conducted to determine the feasibility of a high intensity exercise programme and explore safety and efficacy outcomes in patients with HCM. Methods: Participants were randomized to a 12-week supervised exercise programme (n = 40) in addition to usual care, or usual care alone (n = 40). All participants underwent assessment at baseline and 12 weeks. The exercise group was re-evaluated 6 months post-programme. Feasibility was assessed by (i) recruitment, adherence, and retention rates; (ii) staffing ratios; (iii) logistics; and (iv) acceptability of the intervention. The primary exploratory safety outcome was a composite of arrhythmia-related events. Exploratory secondary outcomes included changes in (i) cardiorespiratory fitness; (ii) cardiovascular risk factors; and (iii) quality of life, anxiety, and depression scores. Results: Overall, 67 (84%) participants completed the study (n = 34 and n = 33 in the exercise and usual care groups, respectively). Reasons for non-adherence included travel, work, and family commitments. Resource provision complied with national cardiac rehabilitation standards. There was no difference between groups for the exploratory safety outcome (P = .99). At 12 weeks, the exercise group had a greater increase in peak oxygen consumption (VO2) [+4.1 mL/kg/min, 95% confidence interval (CI) 1.1, 7.1] and VO2 at anaerobic threshold (+2.3 mL/kg/min, 95% CI 0.4, 4.1), lower systolic blood pressure (−7.3 mmHg, 95% CI −11.7, −2.8) and body mass index (−0.8 kg/m2, 95% CI −1.1, −0.4), and greater improvement in hospital anxiety (−3, 95% CI −4.3, −1.7) and depression (−1.7, 95% CI −2.9, −0.5) scores, compared to the usual care group. Most exercise gains dissipated at 6 months. Conclusions: A high intensity exercise programme is feasible in patients with HCM, with apparent cardiovascular and psychological benefits, and no increase in arrhythmias. A large-scale study is required to substantiate findings and assess long-term safety of high intensity exercise in HCM.
- Open Access
- 21 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (21) , 1693-1695
Type 1 Brugada Pattern May Be Provoked by Ajmaline in Some Healthy Subjects: Results From a Clinical Trial
- 21 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (21) , 1693-1695
Open AccessType 1 Brugada Pattern May Be Provoked by Ajmaline in Some Healthy Subjects: Results From a Clinical Trial
- 27 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (12) , 1054-1061
Prevalence and clinical significance of electrocardiographic complete right bundle branch block in young individuals
Aims: There is limited information on the clinical significance of complete right bundle branch block (CRBBB) in young individuals. The aim of this study was to determine the prevalence and significance of CRBBB in a large cohort of young individuals aged 14–35 years old. Methods and results: From 2008 to 2018, 104,369 consecutive individuals underwent cardiovascular assessment with a health questionnaire, electrocardiogram, clinical consultation, and selective echocardiography. Follow-up was obtained via direct telephone consultations. Mean follow-up was 7.3 ± 2.7 years. CRBBB was identified in 154 (0.1%) individuals and was more prevalent in males compared with females (0.20 vs. 0.06%; P < 0.05) and in athletes compared with non-athletes (0.25 vs. 0.14%; P < 0.05). CRBBB-related cardiac conditions were identified in seven (5%) individuals (four with atrial septal defect, one with Brugada syndrome, one with progressive cardiac conduction disease, and one with atrial fibrillation). Pathology was more frequently identified in individuals with non-isolated CRBBB compared with individuals with isolated CRBBB (14 vs. 1%; P < 0.05) and in individuals with a QRS duration of ≥130 ms compared with individuals with a QRS of <130 ms (10 vs. 1%; P < 0.05). Conclusion: The prevalence of CRBBB in young individuals was 0.1% and was more prevalent in males and in athletes. CRBBB-related conditions were identified in 5% of individuals and were more common in individuals with non-isolated CRBBB and more pronounced intraventricular conduction delay (QRS duration of ≥130 ms). Secondary evaluation should be considered for young individuals with CRBBB with symptoms, concerning family history, additional electrocardiographic anomalies, or significant QRS prolongation (≥130 ms).
- 27 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (12) , 1054-1061
Prevalence and clinical significance of electrocardiographic complete right bundle branch block in young individuals
Aims: There is limited information on the clinical significance of complete right bundle branch block (CRBBB) in young individuals. The aim of this study was to determine the prevalence and significance of CRBBB in a large cohort of young individuals aged 14–35 years old. Methods and results: From 2008 to 2018, 104,369 consecutive individuals underwent cardiovascular assessment with a health questionnaire, electrocardiogram, clinical consultation, and selective echocardiography. Follow-up was obtained via direct telephone consultations. Mean follow-up was 7.3 ± 2.7 years. CRBBB was identified in 154 (0.1%) individuals and was more prevalent in males compared with females (0.20 vs. 0.06%; P < 0.05) and in athletes compared with non-athletes (0.25 vs. 0.14%; P < 0.05). CRBBB-related cardiac conditions were identified in seven (5%) individuals (four with atrial septal defect, one with Brugada syndrome, one with progressive cardiac conduction disease, and one with atrial fibrillation). Pathology was more frequently identified in individuals with non-isolated CRBBB compared with individuals with isolated CRBBB (14 vs. 1%; P < 0.05) and in individuals with a QRS duration of ≥130 ms compared with individuals with a QRS of <130 ms (10 vs. 1%; P < 0.05). Conclusion: The prevalence of CRBBB in young individuals was 0.1% and was more prevalent in males and in athletes. CRBBB-related conditions were identified in 5% of individuals and were more common in individuals with non-isolated CRBBB and more pronounced intraventricular conduction delay (QRS duration of ≥130 ms). Secondary evaluation should be considered for young individuals with CRBBB with symptoms, concerning family history, additional electrocardiographic anomalies, or significant QRS prolongation (≥130 ms).
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 16 (6) , e004251
Potential Diagnostic Role for a Combined Postmortem DNA and RNA Sequencing for Brugada Syndrome
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 16 (6) , e004251
Open AccessPotential Diagnostic Role for a Combined Postmortem DNA and RNA Sequencing for Brugada Syndrome
- Open Access
A NOVEL ELECTROCARDIOGRAPHIC PREDICTION MODEL FOR DIAGNOSING CONCEALED BRUGADA SYNDROME: RESULTS FROM A CLINICAL TRIAL OF AJMALINE PROVOCATION IN HEALTHY SUBJECTS
Background: Clinical, electrocardiographic, and genomic factors have been associated with the drug-induced type 1 Brugada pattern (DI-T1BP), in response to sodium channel blocker provocation (SCBP). However, prior analyses have been concerned with prediction of the DI-T1BP rather than the validity of the diagnosis of concealed Brugada syndrome (BrS). We sought to analyse and compare the ECG response to SCBP with ajmaline in a cohort of healthy controls (HC) and a definite BrS group (Def-BrS) to develop a diagnostic score. Methods: Healthy controls (HC) were systematically recruited as part of a clinical trial. Following comprehensive cardiovascular screening, eligible subjects underwent SCBP with ajmaline. We identified a Def-BrS cohort, defined as a DI-T1BP and a Shanghai Score (SS) > 3.5, from consecutive patients with suspected BrS undergoing SCBP with ajmaline using the identical protocol. Def-BrS and HC were divided equally into discovery and validation cohorts. Digital ECG acquisition facilitated automated measurement of ECG parameters. A multivariable analysis compared ECG parameters between the HC and Def-BrS cohorts. A logistic regression analysis identified ECG characteristics that accurately predicted the diagnosis of Def-BrS. This model was then assessed in the validation cohort. Results: Two-hundred-and-forty-eight volunteers completed an online questionnaire, 103 accepted an invitation to undergo further screening and 100 were recruited into the HC group. Three HCs developed a DI-T1BP. From 1241 patients undergoing SCBP, 166 were Def-BrS. There were no demographic differences between the HC discovery and validation groups or between the Def-BrS discovery and validation groups. Following multivariable logistic regression analysis, QRS duration, mean anterior lead ST segment amplitude at baseline, maximum change in QRS duration, anterior ST segment amplitude and QRS area after SCBP, were independently associated with Def-BrS. The combined model was an excellent discriminator for Def-BrS, with an area under the curve of 0.95 [95% confidence interval (CI) = 0.912 – 0.989], P<0.001 in the discovery groups and 0.97 [95% CI = 0.948 – 0.998], P<0.001 in the validation groups. Conclusion: The yield of the DI-T1BP in HCs is 3%. However, there are distinct ECG parameters at baseline and in response to SCBP that favour a definite diagnosis of BrS. These observations permit the quantifiable refinement of the ECG diagnosis of concealed BrS, avoiding the pitfalls of relying upon the DI-T1BP alone.
Open AccessA NOVEL ELECTROCARDIOGRAPHIC PREDICTION MODEL FOR DIAGNOSING CONCEALED BRUGADA SYNDROME: RESULTS FROM A CLINICAL TRIAL OF AJMALINE PROVOCATION IN HEALTHY SUBJECTS
Background: Clinical, electrocardiographic, and genomic factors have been associated with the drug-induced type 1 Brugada pattern (DI-T1BP), in response to sodium channel blocker provocation (SCBP). However, prior analyses have been concerned with prediction of the DI-T1BP rather than the validity of the diagnosis of concealed Brugada syndrome (BrS). We sought to analyse and compare the ECG response to SCBP with ajmaline in a cohort of healthy controls (HC) and a definite BrS group (Def-BrS) to develop a diagnostic score. Methods: Healthy controls (HC) were systematically recruited as part of a clinical trial. Following comprehensive cardiovascular screening, eligible subjects underwent SCBP with ajmaline. We identified a Def-BrS cohort, defined as a DI-T1BP and a Shanghai Score (SS) > 3.5, from consecutive patients with suspected BrS undergoing SCBP with ajmaline using the identical protocol. Def-BrS and HC were divided equally into discovery and validation cohorts. Digital ECG acquisition facilitated automated measurement of ECG parameters. A multivariable analysis compared ECG parameters between the HC and Def-BrS cohorts. A logistic regression analysis identified ECG characteristics that accurately predicted the diagnosis of Def-BrS. This model was then assessed in the validation cohort. Results: Two-hundred-and-forty-eight volunteers completed an online questionnaire, 103 accepted an invitation to undergo further screening and 100 were recruited into the HC group. Three HCs developed a DI-T1BP. From 1241 patients undergoing SCBP, 166 were Def-BrS. There were no demographic differences between the HC discovery and validation groups or between the Def-BrS discovery and validation groups. Following multivariable logistic regression analysis, QRS duration, mean anterior lead ST segment amplitude at baseline, maximum change in QRS duration, anterior ST segment amplitude and QRS area after SCBP, were independently associated with Def-BrS. The combined model was an excellent discriminator for Def-BrS, with an area under the curve of 0.95 [95% confidence interval (CI) = 0.912 – 0.989], P<0.001 in the discovery groups and 0.97 [95% CI = 0.948 – 0.998], P<0.001 in the validation groups. Conclusion: The yield of the DI-T1BP in HCs is 3%. However, there are distinct ECG parameters at baseline and in response to SCBP that favour a definite diagnosis of BrS. These observations permit the quantifiable refinement of the ECG diagnosis of concealed BrS, avoiding the pitfalls of relying upon the DI-T1BP alone.
- Open Access
- 23 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (21) , 1622-1633
Subepicardial Cardiomyopathy: A Disease Underlying J-Wave Syndromes and Idiopathic Ventricular Fibrillation
Brugada syndrome (BrS), early repolarization syndrome (ERS), and idiopathic ventricular fibrillation (iVF) have long been considered primary electrical disorders associated with malignant ventricular arrhythmia and sudden cardiac death. However, recent studies have revealed the presence of subtle microstructural abnormalities of the extracellular matrix in some cases of BrS, ERS, and iVF, particularly within right ventricular subepicardial myocardium. Substrate-based ablation within this region has been shown to ameliorate the electrocardiographic phenotype and to reduce arrhythmia frequency in BrS. Patients with ERS and iVF may also exhibit low-voltage and fractionated electrograms in the ventricular subepicardial myocardium, which can be treated with ablation. A significant proportion of patients with BrS and ERS, as well as some iVF survivors, harbor pathogenic variants in the voltage-gated sodium channel gene, SCN5A , but the majority of genetic susceptibility of these disorders is likely to be polygenic. Here, we postulate that BrS, ERS, and iVF may form part of a spectrum of subtle subepicardial cardiomyopathy. We propose that impaired sodium current, along with genetic and environmental susceptibility, precipitates a reduction in epicardial conduction reserve, facilitating current-to-load mismatch at sites of structural discontinuity, giving rise to electrocardiographic changes and the arrhythmogenic substrate.
- 23 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (21) , 1622-1633
Open AccessSubepicardial Cardiomyopathy: A Disease Underlying J-Wave Syndromes and Idiopathic Ventricular Fibrillation
Brugada syndrome (BrS), early repolarization syndrome (ERS), and idiopathic ventricular fibrillation (iVF) have long been considered primary electrical disorders associated with malignant ventricular arrhythmia and sudden cardiac death. However, recent studies have revealed the presence of subtle microstructural abnormalities of the extracellular matrix in some cases of BrS, ERS, and iVF, particularly within right ventricular subepicardial myocardium. Substrate-based ablation within this region has been shown to ameliorate the electrocardiographic phenotype and to reduce arrhythmia frequency in BrS. Patients with ERS and iVF may also exhibit low-voltage and fractionated electrograms in the ventricular subepicardial myocardium, which can be treated with ablation. A significant proportion of patients with BrS and ERS, as well as some iVF survivors, harbor pathogenic variants in the voltage-gated sodium channel gene, SCN5A , but the majority of genetic susceptibility of these disorders is likely to be polygenic. Here, we postulate that BrS, ERS, and iVF may form part of a spectrum of subtle subepicardial cardiomyopathy. We propose that impaired sodium current, along with genetic and environmental susceptibility, precipitates a reduction in epicardial conduction reserve, facilitating current-to-load mismatch at sites of structural discontinuity, giving rise to electrocardiographic changes and the arrhythmogenic substrate.
- Open Access
Prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players
Background and aim The efficacy of pre-COVID-19 and post-COVID-19 infection 12-lead ECGs for identifying athletes with myopericarditis has never been reported. We aimed to assess the prevalence and significance of de-novo ECG changes following COVID-19 infection. Methods In this multicentre observational study, between March 2020 and May 2022, we evaluated consecutive athletes with COVID-19 infection. Athletes exhibiting de-novo ECG changes underwent cardiovascular magnetic resonance (CMR) scans. One club mandated CMR scans for all players (n=30) following COVID-19 infection, despite the absence of cardiac symptoms or de-novo ECG changes. Results 511 soccer players (median age 21 years, IQR 18–26 years) were included. 17 (3%) athletes demonstrated de-novo ECG changes, which included reduction in T-wave amplitude in the inferior and lateral leads (n=5), inferior leads (n=4) and lateral leads (n=4); inferior T-wave inversion (n=7); and ST-segment depression (n=2). 15 (88%) athletes with de-novo ECG changes revealed evidence of inflammatory cardiac sequelae. All 30 athletes who underwent a mandatory CMR scan had normal findings. Athletes revealing de-novo ECG changes had a higher prevalence of cardiac symptoms (71% vs 12%, pConclusions 3% of athletes demonstrated de-novo ECG changes post COVID-19 infection, of which 88% were diagnosed with cardiac inflammation. Most affected athletes exhibited cardiac symptoms; however, de-novo ECG changes contributed to a diagnosis of cardiac inflammation in 20% of athletes without cardiac symptoms.
Open AccessPrevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players
Background and aim The efficacy of pre-COVID-19 and post-COVID-19 infection 12-lead ECGs for identifying athletes with myopericarditis has never been reported. We aimed to assess the prevalence and significance of de-novo ECG changes following COVID-19 infection. Methods In this multicentre observational study, between March 2020 and May 2022, we evaluated consecutive athletes with COVID-19 infection. Athletes exhibiting de-novo ECG changes underwent cardiovascular magnetic resonance (CMR) scans. One club mandated CMR scans for all players (n=30) following COVID-19 infection, despite the absence of cardiac symptoms or de-novo ECG changes. Results 511 soccer players (median age 21 years, IQR 18–26 years) were included. 17 (3%) athletes demonstrated de-novo ECG changes, which included reduction in T-wave amplitude in the inferior and lateral leads (n=5), inferior leads (n=4) and lateral leads (n=4); inferior T-wave inversion (n=7); and ST-segment depression (n=2). 15 (88%) athletes with de-novo ECG changes revealed evidence of inflammatory cardiac sequelae. All 30 athletes who underwent a mandatory CMR scan had normal findings. Athletes revealing de-novo ECG changes had a higher prevalence of cardiac symptoms (71% vs 12%, pConclusions 3% of athletes demonstrated de-novo ECG changes post COVID-19 infection, of which 88% were diagnosed with cardiac inflammation. Most affected athletes exhibited cardiac symptoms; however, de-novo ECG changes contributed to a diagnosis of cardiac inflammation in 20% of athletes without cardiac symptoms.
- Open Access
- 21 October 2022
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 11, e20
Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterised by adenergically mediated bidirectional and/or polymorphic ventricular tachycardia. CPVT is a significant cause of autopsy-negative sudden death in children and adolescents, although it can also affect adults. It is often caused by pathogenic variants in the cardiac ryanodine receptor gene as well as other rarer genes. Early identification and risk stratification is of major importance. β-blockers are the cornerstone of therapy. Sodium channel blockers, specifically flecainide, have an additive role. Left cardiac sympathetic denervation is playing an increasing role in suppression of arrhythmia and symptoms. Concerns have been raised, however, about the efficacy of implantable cardioverter defibrillator therapy and the risk of catecholamine driven proarrhythmic storms. In this review, we summarise the clinical characteristics, genetics, and diagnostic and therapeutic strategies for CPVT and describe recent advances and challenges.
- 21 October 2022
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 11, e20
Open AccessCatecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterised by adenergically mediated bidirectional and/or polymorphic ventricular tachycardia. CPVT is a significant cause of autopsy-negative sudden death in children and adolescents, although it can also affect adults. It is often caused by pathogenic variants in the cardiac ryanodine receptor gene as well as other rarer genes. Early identification and risk stratification is of major importance. β-blockers are the cornerstone of therapy. Sodium channel blockers, specifically flecainide, have an additive role. Left cardiac sympathetic denervation is playing an increasing role in suppression of arrhythmia and symptoms. Concerns have been raised, however, about the efficacy of implantable cardioverter defibrillator therapy and the risk of catecholamine driven proarrhythmic storms. In this review, we summarise the clinical characteristics, genetics, and diagnostic and therapeutic strategies for CPVT and describe recent advances and challenges.